Skip to main content

TPG-Reliance Retail deal: Global investment company to inject Rs 1,837.5 crore for 0.41% of RIL unit

This marks the second investment by TPG in a subsidiary of Reliance Industries, after a Rs 4,546.8 crore investment in Jio Platforms announced earlier this year. Reliance Retail has so far raised Rs 32,197.5 crore from a clutch of global investors in exchange for a combined 7.28 percent stake.

Global investment firm TPG will inject Rs 1,837.5 crore in the retail division of Reliance Industries (RIL) for a 0.41 percent stake, marking the seventh investment in recent weeks as global investor interest in the company ascends by the day.

The latest investment values Reliance Retail at a pre-money equity value of Rs 4.285 lakh crore, RIL said in a late night statement (October 3), moments after it announced that Singapore investment company GIC will invest Rs 5,512.5 crore in the company.



TPG is making the investment from its TPG Capital Asia fund.

This marks the second investment by TPG in a subsidiary of Reliance Industries, after a Rs 4,546.8 crore investment in Jio Platforms announced earlier this year.

 

Reliance Retail has so far raised Rs 32,197.5 crore from a clutch of global investors in exchange for a combined 7.28 percent stake.

Mukesh Ambani, Chairman and Managing Director of Reliance Industries, said, “TPG has a proven track record of being a valuable partner to global technology businesses and industry leaders and we look forward to their guidance and support in our journey.”

Jim Coulter, Co-CEO, TPG, said, “Reliance Industries has utilised technology and scale to position Reliance Retail as an incredibly strong, well-organized, and innovative leader. We are excited to join with them as they seek to create a more inclusive retail industry that allows kiranas and Indian consumers to benefit from the connectivity, efficiency, and accessibility of the Reliance Retail omnichannel platform.”

On October 2, Singapore investment company GIC said it will invest Rs 5,512.5 crore in exchange for 1.22 percent stake.

On October 1, Abu Dhabi state fund Mubadala Investment Co said it will invest Rs 6,247.5 crore to secure 1.4 percent in the retail unit of RIL.

This investment —  with Silver Lake's co-investors and General Atlantic, the seventh in three weeks — too valued Reliance Retail at a pre-money equity value of Rs 4.285 lakh crore.

Reliance Retail operates India's largest, fastest growing and most profitable retail business serving close to 640 million footfalls across its nearly 12,000 stores nationwide.

TPG is a leading global alternative asset firm founded in 1992 with more than $83 billion of assets under management across a wide range of asset classes, including private equity, growth equity, real estate and public equity.

Over TPG’s nearly 30-year history, the firm has built an ecosystem made up of hundreds of portfolio companies and a value-added network of professionals, executives, and advisors around the world. By offering institutional support and global resources, TPG enables these companies to reach their full potential and unlock greater possibilities.

Morgan Stanley acted as financial advisor to Reliance Retail and Cyril Amarchand Mangaldas and Davis Polk & Wardwell acted as legal counsels.

Source - Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more